Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.08	$0.84	$0.64 ▼ $2.14	$42.85M	-0.8	37,223 shs	25,542 shs
CTXR Citius Pharmaceuticals	$0.77 +12.9%	$0.90	$0.65 ▼ $26.25	$7.37M	0.9	188,191 shs	233,549 shs
EGRX Eagle Pharmaceuticals	$2.00 +5.3%	$1.70	$1.50 ▼ $2.13	$25.97M	0.83	9,724 shs	304 shs
KALA KALA BIO	$3.57 -4.0%	$3.90	$2.92 ▼ $11.20	$23.29M	-1.91	93,735 shs	17,276 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+62.08%	+16.23%	+9.28%	-44.50%
CTXR Citius Pharmaceuticals	0.00%	-1.65%	-10.09%	-55.68%	-96.03%
EGRX Eagle Pharmaceuticals	0.00%	-5.00%	-3.55%	+58.33%	-45.24%
KALA KALA BIO	0.00%	-9.16%	-2.13%	-47.50%	-45.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.4886 of 5 stars	3.5	5.0	0.0	0.0	3.6	0.8	1.3
CTXR Citius Pharmaceuticals	2.7005 of 5 stars	3.4	4.0	0.0	0.0	1.9	0.8	1.3
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	3.8991 of 5 stars	3.5	3.0	0.0	4.4	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$5.17	378.40% Upside
CTXR Citius Pharmaceuticals	2.80	Moderate Buy	$54.50	6,996.35% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.50	278.15% Upside

Current Analyst Ratings Breakdown

Latest CTXR, BRNS, KALA, and EGRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/24/2025	BRNS Barinthus Biotherapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/21/2025	BRNS Barinthus Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	2.90	N/A	N/A	$4.85 per share	0.22
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$8.02 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.10	$5.00 per share	0.40	N/A	∞
KALA KALA BIO	$3.89M	5.92	N/A	N/A	$2.79 per share	1.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$73.35M	-$1.64	N/A	N/A	N/A	N/A	-34.26%	-29.30%	8/7/2025 (Estimated)
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	0.61	N/A	N/A	-51.69%	-37.60%	8/11/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	-$42.20M	-$8.24	N/A	N/A	N/A	N/A	-448.61%	-69.37%	8/5/2025 (Estimated)

Latest CTXR, BRNS, KALA, and EGRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A
5/7/2025	Q1 2025	BRNS Barinthus Biotherapeutics	-$0.34	-$0.49	-$0.15	-$0.49	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A
3/20/2025	Q4 2024	BRNS Barinthus Biotherapeutics	-$0.50	-$0.51	-$0.01	-$0.51	N/A	$14.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	8.93	8.93
CTXR Citius Pharmaceuticals	N/A	0.41	0.17
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
KALA KALA BIO	3.18	2.15	2.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
CTXR Citius Pharmaceuticals	16.88%
EGRX Eagle Pharmaceuticals	85.36%
KALA KALA BIO	24.61%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
CTXR Citius Pharmaceuticals	12.10%
EGRX Eagle Pharmaceuticals	28.90%
KALA KALA BIO	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.24 million	37.01 million	N/A
CTXR Citius Pharmaceuticals	20	9.83 million	7.55 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
KALA KALA BIO	30	6.45 million	5.58 million	Not Optionable

CTXR, BRNS, KALA, and EGRX Headlines

Recent News About These Companies

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Q1 Earnings Forecast for KALA BIO Issued By HC Wainwright

May 27, 2025 | americanbankingnews.com

HC Wainwright Cuts KALA BIO (NASDAQ:KALA) Price Target to $12.00

May 25, 2025 | americanbankingnews.com

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | finance.yahoo.com

Chief Minister cancels programme over unauthorised nature of venue

April 20, 2025 | thehindu.com

KALA BIO: Q4 Earnings Snapshot

March 31, 2025 | timesunion.com

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | markets.businessinsider.com

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | finance.yahoo.com

Kala Bio announces CEO departure, appoints interim leader

February 13, 2025 | msn.com

KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | finanznachrichten.de

Kala Bio appoints new interim CEO amid leadership shuffle

February 12, 2025 | msn.com

Kala announces resignation of CEO Iwicki, Bazemore appointed interim CEO

February 12, 2025 | markets.businessinsider.com

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

February 12, 2025 | msn.com

KALA BIO Announces Chief Executive Officer Transition

February 12, 2025 | globenewswire.com

KALA stock soars to 52-week high, reaching $8.81

January 29, 2025 | msn.com

Kala Pharmaceuticals files to sell 1.67M shares of common stock for holders

January 24, 2025 | markets.businessinsider.com

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock

January 8, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

January 1, 2025 | insidertrades.com

KALA BIO, Inc. Secures $10.75 Million in Private Placement to Advance Clinical Development of KPI-012

December 30, 2024 | quiverquant.com

KALA BIO Announces $10,750,000 Private Placement

December 30, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, BRNS, KALA, and EGRX Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.08 0.00 (-0.28%)

As of 04:00 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Citius Pharmaceuticals NASDAQ:CTXR

$0.77 +0.09 (+13.38%)

As of 04:00 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Eagle Pharmaceuticals NASDAQ:EGRX

$2.00 +0.10 (+5.26%)

As of 10:24 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

KALA BIO NASDAQ:KALA

$3.53 -0.19 (-5.05%)

As of 04:00 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time